AXGN's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 216.67 -- higher than 85.99% of US-listed equities with positive expected earnings growth.
Axogen Inc's stock had its IPO on March 27, 1990, making it an older stock than 84.52% of US equities in our set.
With a year-over-year growth in debt of 1,376.61%, Axogen Inc's debt growth rate surpasses 98.52% of about US stocks.
If you're looking for stocks that are quantitatively similar to Axogen Inc, a group of peers worth examining would be SNES, SPNE, PWFL, ISR, and OXFD.
AXGN's SEC filings can be seen here. And to visit Axogen Inc's official web site, go to www.axogeninc.com.
Small-cap med-tech AxoGen (AXGN) already had plenty of long-running challenges to deal with before the pandemic, and the decline in elective pressures has only added to the challenges and pressures. While AxoGen’s core product offers what I believe to be meaningful advantages over autografts and synthetic conduits, the company’s sales...
Stephen Simpson, CFA on Seeking Alpha | October 2, 2020
DUBLIN--(BUSINESS WIRE)--The "Nerve Repair and Regeneration - Global Market Outlook (2018-2027)" report has been added to ResearchAndMarkets.com's offering. The Global Nerve Repair and Regeneration market accounted for $6.46 billion in 2018 and is expected to reach $21.68 billion by 2027 growing at a CAGR of 14.4% during the forecast period. Some of the key factors propelling the market growth are technological developments for nerve repair and regeneration and an increase in healthcare expense
RECON is a pivotal study supporting the Company’s Biologics License Application (BLA) for Avance® Nerve GraftALACHUA, Fla., July 22, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that its phase 3 pivotal RECONSM Clinical Study supporting its Biologics License Application (BLA) submission for Avance Nerve Graft has reached its enrollment target of 220 subjects. RECON compares Avance Nerve Graft to manufactured conduits in digital nerve injuries with a primary endpoint of return of sensation and secondary endpoints for quality of life and patient satisfaction. “We are pleased to have reached this important milestone and appreciate the dedicatio...